Skip to main content
SpringerLink
Log in

Telithromycin

A Viewpoint by S. Ragnar Norrby

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bemer-Melchior P, Juvin M-E, Tassin S, et al. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother 2000 Nov; 44: 2999–3002

    Article  PubMed  CAS  Google Scholar 

  2. Malathum K, Coque TM, Singh KV, et al. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against Gram-positive bacteria. Antimicrob Agents Chemother 1999 Apr; 43: 930–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases and Medical Microbiology, Lund University Hospital, University of Lund, Lund, Sweden

    S. Ragnar Norrby

Authors
  1. S. Ragnar Norrby
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ragnar Norrby, S. Telithromycin. Drugs 61, 830 (2001). https://doi.org/10.2165/00003495-200161060-00017

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161060-00017

Search

Navigation